| Date Filed | Type | Description |
| 10/12/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 10/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 10/02/2023 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
SC 13D/A
| Novo Holdings A/S reports a 4.4% stake in Cyteir Therapeutics, Inc. |
| 07/26/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/18/2023 |
4
| Novo Holdings A/S (10% Owner) has filed a Form 4 on Cyteir Therapeutics, Inc.|
Txns:
| Sold 11,000 shares
@ $2.7365, valued at
$30.1k
Sold 21,100 shares
@ $2.7488, valued at
$58k
Sold 6,500 shares
@ $2.7574, valued at
$17.9k
|
|
| 07/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/10/2023 |
SC 13G/A
| FMR LLC reports a 2.3% stake in CYTEIR THERAPEUTICS INC |
| 07/03/2023 |
4
| Novo Holdings A/S (10% Owner) has filed a Form 4 on Cyteir Therapeutics, Inc.|
Txns:
| Sold 200,937 shares
@ $2.6341, valued at
$529.3k
|
|
| 06/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/30/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/28/2023 |
4
| Novo Holdings A/S (10% Owner) has filed a Form 4 on Cyteir Therapeutics, Inc.|
Txns:
| Sold 8,437 shares
@ $1.7905, valued at
$15.1k
Sold 31,978 shares
@ $1.7727, valued at
$56.7k
|
|
| 06/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/31/2023 |
8-K
| Resignation/termination of a director |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 03/23/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7% stake in Cyteir Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 5.1% stake in Cyteir Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
4
| Zakrzewski Joseph S (Director) has filed a Form 4 on Cyteir Therapeutics, Inc.|
Txns:
| Granted 14,150 options to buy
@ $1.69, valued at
$23.9k
|
|
| 02/07/2023 |
4
| THERO JOHN F (Director) has filed a Form 4 on Cyteir Therapeutics, Inc.|
Txns:
| Granted 12,828 options to buy
@ $1.69, valued at
$21.7k
|
|
|